Literature DB >> 18842264

Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease.

M de Fost1, M Langeveld, R Franssen, B A Hutten, J E M Groener, E de Groot, M M Mannens, H Bikker, J M F G Aerts, J J P Kastelein, C E M Hollak.   

Abstract

OBJECTIVE: A low plasma high-density lipoprotein cholesterol (HDL-c) concentration is an important risk factor for the development of atherosclerotic cardiovascular disease. HDL-c levels are abnormally low in type I Gaucher disease (GD) patients. The aim of this study was to determine whether GD is associated with premature atherosclerosis.
METHODS: Lipid profiles, apolipoproteins, and carotid artery intima-media thickness (cIMT) were analyzed in 40 type I GD patients, 34 carriers and 41 control subjects. cIMT is a non-invasive validated biomarker for the status of atherosclerosis and present and future cardiovascular disease risk.
RESULTS: Compared to control subjects, patients showed decreased HDL-c (1.1+/-0.3 mmol/L) as well as mildly decreased low-density lipoprotein cholesterol (LDL-c) levels (2.8+/-0.7 mmol/L), with an increased ApoB/ApoA1 ratio. In carriers, HDL-c levels were normal, but LDL-c levels were decreased (2.7+/-0.8 mmol/L). Mean cIMT measurements were not different in the three study groups (patients: 0.63+/-0.1mm versus carriers: 0.64+/-0.1mm versus control subjects: 0.65+/-0.1 mm).
CONCLUSION: In Gaucher disease low HDL-c levels do not lead to premature atherosclerosis as assessed by cIMT measurement. This indicates that the inverse relationship between levels of HDL-c and risk of cardiovascular disease in the general population may not be present in all conditions characterised by low HDL-c levels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18842264     DOI: 10.1016/j.atherosclerosis.2008.08.027

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  9 in total

1.  Dynamic changes of lipid profile in Romanian patients with Gaucher disease type 1 under enzyme replacement therapy: a prospective study.

Authors:  Anca Zimmermann; Paula Grigorescu-Sido; Heidi Rossmann; Karl J Lackner; Cristina Drugan; Camelia Al Khzouz; Simona Bucerzan; Ioana Naşcu; Tim Zimmermann; Daniel Leucuţa; Matthias M Weber
Journal:  J Inherit Metab Dis       Date:  2012-09-14       Impact factor: 4.982

2.  Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity.

Authors:  Philip Stein; Ruhua Yang; Jun Liu; Gregory M Pastores; Pramod K Mistry
Journal:  J Inherit Metab Dis       Date:  2011-02-03       Impact factor: 4.982

3.  Gaucher disease: resetting the clinical and scientific agenda.

Authors:  Pramod K Mistry; Neal J Weinreb; Roscoe O Brady; Gregory A Grabowski
Journal:  Am J Hematol       Date:  2009-04       Impact factor: 10.047

4.  Bis(monoacylglycero)phosphate accumulation in macrophages induces intracellular cholesterol redistribution, attenuates liver-X receptor/ATP-Binding cassette transporter A1/ATP-binding cassette transporter G1 pathway, and impairs cholesterol efflux.

Authors:  Céline Luquain-Costaz; Etienne Lefai; Maud Arnal-Levron; Daria Markina; Shota Sakaï; Vanessa Euthine; Asami Makino; Michel Guichardant; Shizuya Yamashita; Toshihide Kobayashi; Michel Lagarde; Philippe Moulin; Isabelle Delton-Vandenbroucke
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-06-20       Impact factor: 8.311

Review 5.  Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies.

Authors:  Johannes M F G Aerts; Wouter W Kallemeijn; Wouter Wegdam; Maria Joao Ferraz; Marielle J van Breemen; Nick Dekker; Gertjan Kramer; Ben J Poorthuis; Johanna E M Groener; Josanne Cox-Brinkman; Saskia M Rombach; Carla E M Hollak; Gabor E Linthorst; Martin D Witte; Henrik Gold; Gijs A van der Marel; Herman S Overkleeft; Rolf G Boot
Journal:  J Inherit Metab Dis       Date:  2011-03-29       Impact factor: 4.982

Review 6.  A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.

Authors:  Jérôme Stirnemann; Nadia Belmatoug; Fabrice Camou; Christine Serratrice; Roseline Froissart; Catherine Caillaud; Thierry Levade; Leonardo Astudillo; Jacques Serratrice; Anaïs Brassier; Christian Rose; Thierry Billette de Villemeur; Marc G Berger
Journal:  Int J Mol Sci       Date:  2017-02-17       Impact factor: 5.923

7.  Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

Authors:  Deborah Elstein; Ari Zimran
Journal:  Biologics       Date:  2009-09-15

8.  High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease.

Authors:  Tamar H Taddei; James Dziura; Shu Chen; Ruhua Yang; Hideyuki Hyogo; Cameron Sullards; David E Cohen; Gregory Pastores; Pramod K Mistry
Journal:  J Inherit Metab Dis       Date:  2010-03-31       Impact factor: 4.982

9.  PEGylated IL-10 Activates Kupffer Cells to Control Hypercholesterolemia.

Authors:  Ivan H Chan; Dennis Van Hoof; Marina Abramova; Melissa Bilardello; Elliot Mar; Brett Jorgensen; Scott McCauley; Harminder Bal; Martin Oft; Peter Van Vlasselaer; John B Mumm
Journal:  PLoS One       Date:  2016-06-14       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.